Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Riluzole Oral Soluble Film in ALS
NCT03457753Phase 2Withdrawn
- Sponsor
- Aquestive Therapeutics
- Start
- Mar 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of riluzole in amyotrophic lateral sclerosis (ALS), sponsored by Aquestive Therapeutics. Planned start Mar 2018; status: withdrawn.
02
Drugs
riluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03457753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457753.